ArticleBMC cancer2025
Dynamic CEA kinetics as a prognostic biomarker for HER2-negative advanced gastric cancer treated with chemoimmunotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed death-1 (PD-1) inhibitors combined with chemotherapy have become a standard treatment for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (GC). However, responses vary, and effective prognostic biomarkers are needed. This study aimed to investigate the prognostic value of dynamic changes in carcinoembryonic antigen (CEA) levels in this patient population.
methodsThis retrospective cohort study included 96 patients with HER2-negative metastatic or locally advanced GC treated at our institution between June 2021 and June 2024. All patients received PD-1 inhibitors plus chemotherapy. Serial CEA measurements were used to construct a linear model (Y = ax + b) for each patient, where 'a' represents the slope of CEA change. Using a receiver operating characteristic (ROC) curve analysis for predicting 6-month progression-free survival (PFS), an optimal cutoff slope of a = 0.85 was determined. Patients were stratified into a Slow-riser group (a ≤ 0.85, n = 70) and a Rapid-riser group (a > 0.85, n = 26). We compared treatment efficacy, survival outcomes, and adverse events between the groups. Prognostic factors for PFS were identified using univariate and multivariate Cox proportional hazards models, in line with TRIPOD principles.
resultsDuring treatment, serial CEA levels exhibited a fluctuating pattern with an overall upward trend. Compared to the Rapid-riser group, the Slow-riser group had a significantly higher disease control rate (DCR) (71.4% vs. 46.2%, P = 0.028) and a lower incidence of progressive disease (PD) (24.3% vs. 53.8%, P = 0.012). The Slow-riser group also experienced a lower incidence of grade ≥ 3 adverse events (22.9% vs. 46.2%, P = 0.040). The median PFS (mPFS) was significantly longer in the Slow-riser group than in the Rapid-riser group (3.9 vs. 2.4 months, P = 0.022), although median overall survival (mOS) was not statistically different (16.3 vs. 12.7 months, P = 0.245). Multivariate Cox regression analysis identified CEA trend (Rapid-riser vs. Slow-riser: HR 7.15, 95% CI 2.85-12.11, P < 0.001), number of metastatic sites, peritoneal metastasis, liver metastasis, ECOG performance status, and differentiation grade as independent predictors of poor PFS.
conclusionThe dynamic trajectory of CEA levels during treatment is a significant and independent prognostic factor for patients with HER2-negative advanced GC receiving PD-1 inhibitors plus chemotherapy. Slower CEA elevation is associated with better disease control, improved safety, and longer PFS. Monitoring dynamic CEA changes could be a valuable, accessible tool for clinical risk assessment and patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.